Taysha gene therapies announces sponsored genetic testing for giant axonal neuropathy (gan) in partnership with genedx as well as a collaboration with hereditary neuropathy foundation and charcot-marie-tooth association centers of excellence

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced sponsored genetic testing for giant axonal neuropathy (gan) in partnership with genedx, inc., a leader in genomic analysis and a wholly owned subsidiary of bioreference labo
TSHA Ratings Summary
TSHA Quant Ranking